1 / 45

Transfusion Post Allogeneic Stem Cell Transplant

Transfusion Post Allogeneic Stem Cell Transplant. Robert C. Skeate, MD MS. Overview. Discuss stem cell sources for transplant -Advantages and disadvantages -Double cord blood transplants and why they are done That ABO type is not often a consideration Consequences of ABO mismatch

sutton
Télécharger la présentation

Transfusion Post Allogeneic Stem Cell Transplant

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transfusion Post Allogeneic Stem Cell Transplant Robert C. Skeate, MD MS

  2. Overview • Discuss stem cell sources for transplant-Advantages and disadvantages-Double cord blood transplants and why they are done • That ABO type is not often a consideration • Consequences of ABO mismatch • Natural history of ABO type post transplant • Choosing blood products post transplant • Investigation of increasing O neg blood use at the medical center where I previously worked

  3. Options for Stem Cell Transplant • Obtain stem cells directly from bone marrow • Obtained via invasive procedure in the operating room • Are able to collect all the cells you need

  4. Options for Stem Cell Transplant • Peripheral blood stem cells • Very often can obtain needed cell dose

  5. Options for Stem Cell Transplant • Cord Blood • Limiting factor is small cell dose

  6. Choosing a Stem Cell Product • Most important parameter: HLA match-Prefer a matched sibling donor (30%)-Want a “6 out of 6” match-HLA-A, HLA-B, and HLA-DR genes-Typically use PBSC, but can do marrow if unable to get enough cells via apheresis • No matched sibling?-Unrelated HLA matched donor (30%)-Not enough donors (HLA type and race)-Many month delay before transplant Majhail, N, Brunstein, C, & Wagner, J. Double umbilical cord blood transplantation. Current Opinion in Immunology 2006; 18:571–575

  7. Choosing a Stem Cell Product • HLA-matched unrelated cord blood • Cell dose needed = (TNC) 2.5 X 107/ Kg • Only 25% of adults are small enough given typical cell doses in cord blood units • Can increase the dose by using two cord blood units (double cord blood transplant) • Sustained hematopoiesis after DUCBT is usually from one donor • Increasingly common at U of MN Majhail, N, Brunstein, C, & Wagner, J. Double umbilical cord blood transplantation. Current Opinion in Immunology 2006; 18:571–575

  8. Advantages of Cord Blood • Ease of procurement • Absence of risk for donors • Decrease likelihood of infections (CMV) • Store HLA-typed units frozen for rapid use Cord compared to unrelated matched PBSC • Decreased graft-vs-host disease • Similar long term survival • Less well HLA-matched have similar outcome Gluckman, E. History of cord blood transplantation. Bone Marrow Transplantation 2009; 44:621–626

  9. Bensinger, W, and Storb, R. Allogeneic peripheral blood stem cell transplant. Rev Clin Exp Hematol 2001; 5(2):67-86

  10. Haspel, R & Ballen, K. Double cord blood transplants: filling a niche? Stem Cell Rev 2006; 2(2):81-6

  11. Brunstein, C & Laughlin, MJ. Extending cord blood transplant to adults: dealing with problems and results overall. Semin Hematol 2010; 47(1):86-96

  12. What Parameter Not Considered? • Donor and recipient ABO type • Recipients become donor ABO type over time so one would think this would have an impact • 25% or so are mismatched for ABO • ABO mismatch does not impact:-Overall graft failure-Graft vs. host disease-Survival Yazer, M. & Triulzi, D Immune hemolysis following ABO mismatched stem cell or solid organ transplantation. Current Opinion in Hematology 2007, 14:664–670

  13. Consequences to ABO Mismatch • There is a downside to ABO mismatch • Antibodies stay around for many weeks post-transplant • Destroy red cells and precursors 1. Delayed red cell engraftment • Increased RBC transfusion requirements • Pure red cell aplasia • Post-transplant hemolysis

  14. Consequences to ABO Mismatch • Delayed RBC engraftment:41 days for mismatched20 days for matched • Pure red cell aplasia (Not graft failure?) • Recipients engrafts with white cells and platelets but has no red cell production • ABO antibodies destroy red cell precursors • Frequency 8 - 38% of mismatched Yazer, M. & Triulzi, D Immune hemolysis following ABO mismatched stem cell or solid organ transplantation. Current Opinion in Hematology 2007, 14:664–670

  15. Post-Transplant Hemolysis Example: Recipient A Donor B • Acute hemolysis of the B red cells in the stem cell product by the recipient’s anti-B • Subacute hemolysis of recipient’s A red cells due to anti-A from infused donor lymphocytes (passenger lymphocyte syndrome) • Delayed hemolysis of recipient-type A red cells as the donor immune system engrafts • Do not want to potentiate this by transfusing mismatched red cells

  16. Post-Transplant Hemolysis Petz, L. Immune hemolysis associated with transplantation. Seminars in Hematology 2005; 42:145-155

  17. ABO Type Post-Transplant Over weeks to months, recipient develops donor hematopoiesis and immune function • Recipient red cell type at first • Slowly transitions to donor type • Will have mixed field in the transition • Recipient back type at first (anti-A and/or B) • Is often weak due to chemotherapy • Slow transition to donor back type • Often is weak, incomplete, or not present • Transfused products can obscure transition

  18. Isoagglutinins and RBC Engraftment • Comparison of RBC engraftment to determine if preparative regimen matters • Myeloablative (SCT) PBSC transplant • Non-myeloablative (NST) PBSC transplant • January 1997 - May 2000 at NIH • Groups were concurrent, consecutive patients with HLA matched family members • Major ABO mismatch patients • 16 NST and 12 SCT (90 day survivors) Bolan, C. et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001; 98:1687-1694

  19. Time to Donor RBC “Chimerism” Chimerism = Detect donorRBCs on two consecutiveperipheral blood samples(2 - 5 % donor cells)

  20. Time to absence of Isohemagglutinin

  21. RBC Chimerism and Isohemagglutinin NST Patients

  22. Red Cell Transfusion Strategy Yazer, M., Triulzi, D. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol 2007; 14:664–670

  23. 1993-1997 292 BMTs Before Remove Plasma n = 153 Matched Mismatched n = 139 120 BMTs After Remove Plasma Benjamin, R, & Antin, J.Transfusion 1999; 39: 1273-4

  24. Protocol to Switch to Donor-type Blood Criteria to switch to donor-type blood: 1. Only donor-type red cells present 2. Back-type does not have to match donor to give donor cells* 3. No transfusions for 120 days 4. 100% donor type by molecular studies *Cells must be compatible with back-type

  25. Monthly Percent O- Use UMMC (1/03 – 4/07)

  26. Who Was Using O- RBCs? • We performed a retrospective review of all O- transfusions over a 2 month period • Noted in particular instances where O- cells given to non-O- patients

  27. O- for Non-O- Patients

  28. Which Transplants Used O-Neg? • Retrospective review of all allogeneic stem cell transplants over a 5 month period • Noted transplant type, and whether recipient switched to requiring O or O negative cells post transplant given our policy • 52 allogeneic transplants • 29 one donor (PBSC, CBT, or BMT) • 23 double cord blood transplants (DCBT)

  29. Which Transplants Used O-Neg?

  30. Amount of Blood Products Used McCullough J. Collection and use of stem cells; role of transfusion centers in bone marrow transplantation Vox Sang 1994; 67 (Suppl 3):35-42

  31. Do DCBT Patients Use Blood? • Looked at red cell use in 41 DCBT patients • Participants in the platelet dosing study • Counted RBCs used by switched to O- group

  32. Conclusions • Half the O- cells used in non-O- patients went to stem cell transplant patients • Many non-O- DCBT recipients required O- blood post transplant, and they used a substantial number of O- units • Should alert blood supplier of increased O- blood if implementing a DCBT program • Current DCBT programs should alert blood supplier when DCBT procedures increase

  33. Follow-up Study • Wanted to confirm our findings with a higher number of transplants • Contacted cell therapy lab to see what data were available • Cell therapy lab has database of all transplants and ABO types (donor / recipient) • Pulled data from 1st quarter 2005 to 1st quarter 2008 (n = 566 transplants) • Parameters: transplant type (BMT, PBSC, UCBT, DUCBT), ABO of recipient / donor

  34. Total Transplants Per Quarter

  35. ABO Types / Recipients and Donors SDT DUCBT

  36. Mismatches

  37. Red Cells Post-Transplant

  38. Plasma / Platelets Post-Transplant

  39. Results Summary • The majority (76%) of SDTs require O RBCs • Nearly all DUCBTs (91%) require O RBCs • About a third of DUCBTs require O- RBCs (34%), which is approximately double the percent for SDTs (18%) • Approximately 4 times as many DUCBTs (44%) require AB plasma than do SDTs (12%) • In the majority of cases, choosing matched donors would prevent AB and O- use

  40. Discussion • Why is using more O RBCs problematic? • Universal donor, but many can only receive O • O units needed for reference lab cases • Why is using O- RBCs problematic? • Needed for trauma cases / emergency release • Needed for O- females of child bearing age • Needed for neonatal transfusions • What about AB platelets / plasma? • Surgeons want available for emergency trauma • Plasma exchanges on AB patients • Increased work for the blood bank staff

  41. Implications • DUCBT becoming the predominant transplant • TRALI mitigation • Current effort underway to reduce TRALI • Common strategy is to limit female donation • We need female donors to meet CURRENT AB plasma / platelet demand • Platelet additive solutions • Currently the Europeans use platelet additive solutions to remove much of the plasma • DUCBT programs could push this in the US

  42. Implications • Increased pressure on blood suppliers to not only supply lots of blood, rather to supply the KIND of blood needed for the medical care in the community • Pressure to make more effort to ABO match stem cell products when available? • There ARE clinical consequences to ABO mismatch • There are consequences to the blood supply

  43. Conclusions • Due to very real clinical concerns (hemolysis, delayed red cell engraftment, pure red cell aplasia), blood that is compatible with recipients & donors is necessary • DUCBT becoming more common procedure • Multiple blood types involved in DUCBT procedures results in a requirement for an increased number of rare blood products • 34% require O- RBCs • 44% require AB platelets / plasma

  44. Conclusions • The majority of the time the need for rare blood is due to choosing an ABO incompatible stem cell product • DUCBTs put pressure on blood centers to innovate (platelet additive solutions, apheresis, targeted donor programs, engineering of blood products) to meet increasing need for specific blood products • Pressure on transplant physicians and cell therapy labs to carefully choose products

  45. Blood Types in the US http://www.givebloodtoday.org/images/blood%20type%20compat%20chart.jpg

More Related